Literature DB >> 18492330

A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study.

P R Grahmann1, R K Braun.   

Abstract

SETTING: Aerosolized interferon-gamma (IFN-gamma) leads to transient conversion of sputum smears in multidrug-resistant pulmonary tuberculosis (MDR-TB).
OBJECTIVE: To test long-term conversion of sputum smears using the new Jena protocol.
DESIGN: Four MDR-TB patients were treated with aerosolized recombinant IFN-gamma (rIFN-gamma) twice weekly for 8 weeks and anti-tuberculosis drugs. Patients were monitored clinically and T-cell subpopulations were analyzed.
RESULTS: The treatment was well tolerated. All sputum smears cleared within 6-8 weeks, and radiological signs of recovery lasted in all patients for 73-106 months (the entire follow-up period). Before treatment, a patient with a 20+ year history of TB showed no gammadelta T-cells; these cells appeared during treatment. The proportion of natural killer (NK) cells was enhanced during treatment and remained elevated. The proportion of CD4+/CD25+ T-cells in the blood rose after treatment and remained elevated at 2 and 10 months afterwards. No significant change in T-cell levels appeared in patients with a shorter history of TB, except for a tendency toward a slight increase in gammadelta T-cells during treatment.
CONCLUSION: We invite further confirmation, but aerosolized rIFN-gamma plus anti-microbial treatment cured MDR-TB in this case study. The optimal dosing schedule needs to be determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492330

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis.

Authors:  Allison E Reeme; Halli E Miller; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2013-03-13       Impact factor: 3.131

2.  Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guérin (BCG)-vaccinated healthy subjects.

Authors:  R J Al-Attiyah; A S Mustafa
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

Review 3.  Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Authors:  Aparna Mukherjee; Rakesh Lodha; Sushil Kumar Kabra
Journal:  Expert Opin Pharmacother       Date:  2017-10-09       Impact factor: 3.889

4.  Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

Authors:  Diego L Costa; Eduardo P Amaral; Sivaranjani Namasivayam; Lara R Mittereder; Bruno B Andrade; Alan Sher
Journal:  Front Cell Infect Microbiol       Date:  2021-06-21       Impact factor: 5.293

5.  Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung.

Authors:  Ankan Gupta; Farhan J Ahmad; Faiz Ahmad; Umesh D Gupta; Mohan Natarajan; Vishwamohan Katoch; Sangeeta Bhaskar
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.